COMMUNIQUÉS West-GlobeNewswire

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
02/12/2025
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics , a biopharmaceutical company specializing in developing transformative treatments for rare diseases, announced the initiation of a pivotal Phase III [...]
Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
02/12/2025
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics , a biopharmaceutical company specializing in developing transformative treatments for rare diseases, announced the initiation of a pivotal Phase III [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 48 - 2025
02/12/2025
Aggregated presentation by day and by market Statement of transactions in own shares from November 24th to November 28th 2025 Name of the issue Identity code of the issuer (Legal Entity Identifier) Day of the [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 48 - 2025
02/12/2025
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 24 Novembre au 28 Novembre 2025 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la [...]
GUERBET : Ajustement des objectifs financiers 2025.
02/12/2025
Ajustement des objectifs financiers 2025 Villepinte, le 02 décembre 2025, 17h45 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, annonce une révision à [...]
GUERBET : Adjustment of 2025 financial targets.
02/12/2025
Adjustment of 2025 financial targets Villepinte, 2 December 2025, 5.45 p.m. : Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing a downward revision to [...]
Health-ISAC® Announces results of 2026 Board of Directors Election
02/12/2025
ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Health Information Sharing and Analysis Center (Health-ISAC), the non-profit world-class, industry-led sharing organization that provides the global health sector with a [...]
LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.
02/12/2025
EXOUSIA AI SECURES HIGH-VALUE ORPHAN DRUG DESIGNATION ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. [...]
LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.
02/12/2025
EXOUSIA AI SECURES HIGH-VALUE ORPHAN DRUG DESIGNATION ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. [...]
Precision Neuroscience Recognized for Innovation and Responsible Technology with Two Industry Awards
02/12/2025
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision™) a leader in brain–computer interface (BCI) technology, has been named to Inc. Magazine’s 2025 Best in Business list in the Best [...]
SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
02/12/2025
TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company [...]
INVO Fertility Announces Pricing of $4.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
02/12/2025
SARASOTA, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO” or the “Company”) (NASDAQ: IVF), a healthcare company focused on the fertility market, today announced that it has entered into a securities [...]
Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201
02/12/2025
Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel’s advancement across large unmet-need global markets PHOENIX, Dec. 02, 2025 (GLOBE [...]
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging
02/12/2025
The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also to treat patients [...]
BetaGlue Therapeutics Expands its Clinical Trial in Italy after obtaining from the Italian Ministry of Health Approval to conduct its clinical study in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)
02/12/2025
MILAN, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (“BetaGlue” or the “Company”) a pioneering Italian clinical-stage oncology company developing an innovative radiotherapy solution for the targeted [...]
ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors
02/12/2025
– Dr. Tagliaferri is a proven executive recognized for advancing innovative therapies across immunology, oncology and other serious diseases – SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. ( [...]
Aeroflow Health Celebrates Giving Tuesday Through Donations to Western North Carolina Organizations
02/12/2025
Aeroflow donates several thousand dollars across seven local organizations based in its home state ASHEVILLE, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aeroflow Health , a pioneering healthcare company that leverages [...]
Reema Health Tackles Medicaid Challenges with $19M Series B from LRVHealth and Optum Ventures
02/12/2025
Engagement Model Blending Humans and Technology Drives 3X ROI to Medicaid MCOs MINNEAPOLIS, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Reema Health , the human powered and tech-enabled solution that engages hard-to-reach members [...]
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
02/12/2025
- FDA approval marks Alpha Tau’s fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT’s reach into recurrent prostate cancer - JERUSALEM, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ [...]

Pages